ASRT Stock Cash Flow Statements

Assertio Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Assertio Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30

operating activities
net income	-4,510,000	-57,384,000	-279,544,000	8,470,000	-3,484,000	88,553,000	4,174,000	7,834,000	9,064,000	4,606,000	3,738,000	-14,169,000	4,544,000	-24,353,000	-10,522,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	5,696,000	4,908,000	10,357,000	6,480,000	6,484,000	8,363,000	8,170,000	8,164,000	8,699,000	7,379,000	7,412,000	7,474,000	6,812,000	6,963,000	6,149,000
amortization of debt issuance costs and royalty rights	107,000	105,000	102,000	101,000	147,000	176,000
recurring fair value measurements of assets and liabilities		-17,870,000	-17,020,000	241,000	9,167,000
debt-related expenses		0	0	0	9,918,000
provisions for inventory and other assets	1,428,000	1,159,000	739,000	318,000	1,072,000
stock-based compensation	1,207,000	2,642,000	1,865,000	2,205,000	2,446,000	2,388,000	2,400,000	1,734,000	982,000	949,000	867,000	957,000	772,000	3,886,000	1,511,000
deferred income taxes		29,009,000	48,577,000	-18,000	-1,367,000
changes in assets and liabilities:
accounts receivable	5,054,000	14,804,000	30,116,000	4,858,000	-1,109,000	-677,000	3,857,000	385,000	-4,561,000	-8,216,000	9,323,000	-6,227,000	5,109,000	-5,144,000	-4,470,000
inventories	-2,344,000	3,925,000	-2,387,000	-2,909,000	-3,602,000	1,014,000	-2,578,000	-3,007,000	-2,022,000	-2,049,000	1,362,000	2,324,000	2,631,000	501,000	-1,304,000
prepaid and other assets	1,921,000	-7,938,000	2,480,000	2,465,000	1,824,000	-5,269,000	1,180,000	2,263,000	9,845,000	-2,698,000	-863,000	3,245,000	3,395,000	1,981,000	4,006,000
accounts payable and other accrued liabilities	-134,000	-7,825,000	-26,429,000	5,196,000	-290,000	-3,015,000	-6,948,000	1,266,000	-1,511,000	-6,294,000	-18,472,000	12,816,000	-16,749,000	-10,122,000	-5,110,000
accrued rebates, returns and discounts	-267,000	-1,286,000	-4,458,000	-9,456,000	2,887,000	822,000	-3,727,000	-3,257,000	2,926,000	8,832,000	-1,278,000	-5,028,000	-12,978,000	14,199,000	-3,508,000
interest payable	-650,000	650,000	-650,000	650,000	-1,376,000		-1,032,000	-2,500,000	2,300,000		2,450,000	-2,660,000	2,610,000	-3,461,000	3,075,000
net cash from operating activities	7,508,000	5,707,000	2,579,000	18,601,000	22,717,000	26,697,000	10,045,000	14,430,000	27,426,000	4,131,000	4,654,000	964,000	-4,226,000	-5,982,000	-14,431,000
capex	0	-100,000	0	0	0	0	0	0	0	0	0	0	0	0	-1,000
free cash flows	7,508,000	5,607,000	2,579,000	18,601,000	22,717,000	26,697,000	10,045,000	14,430,000	27,426,000	4,131,000	4,654,000	964,000	-4,226,000	-5,982,000	-14,432,000
investing activities
purchase of sympazan		-139,000	0	-175,000	-105,000
net cash from investing activities		-239,000	4,144,000	-703,000	-105,000	-25,784,000	-371,000	-16,114,000	-404,000					0	-1,000
financing activities
payments in connection with 2027 convertible notes		0	0
payment of direct transaction costs related to convertible debt inducement		0	0	0	-1,119,000
payment of contingent consideration		-8,786,000	0	-8,799,000	-6,609,000	0	-4,000,000	-2,000,000	-1,845,000	-2,312,000	0
payments related to the vesting and settlement of equity awards	-206,000	-128,000	177,000
net cash from financing activities	-206,000	-8,915,000	-10,000	-16,326,000	-18,950,000	-798,000	2,888,000	-7,441,000	-2,443,000	-7,522,000	-356,000	-7,569,000	44,473,000	-7,969,000	-10,234,000
net increase in cash and cash equivalents	7,302,000	-3,447,000	6,713,000	1,572,000	3,662,000	115,000	12,562,000	-9,125,000	24,579,000	-21,916,000	4,298,000	-6,605,000	40,247,000
cash and cash equivalents at beginning of year	73,441,000	0	0	0	64,941,000	0	0	0	36,810,000	0	0	0	20,786,000	0	0
cash and cash equivalents at end of period	80,743,000		6,713,000	1,572,000	68,603,000		12,562,000	-9,125,000	61,389,000	-21,916,000	4,298,000	-6,605,000	61,033,000	-13,951,000	-24,666,000
supplemental disclosure of cash flow information
net cash paid for income taxes	11,000														469,000
cash paid for interest	1,300,000	0	1,300,000	0	2,351,000	0	3,004,000			4,908,000	0			5,498,000	887,000
loss on impairment of intangible assets		40,808,000
gain on extinguishment of debt
changes in assets and liabilities, net of acquisition:
purchases of property and equipment		-100,000	0											0	-1,000
purchase of otrexup						-10,138,000	-371,000	-16,114,000	-404,000
net cash acquired in spectrum merger		0
proceeds from the sale of investments
proceeds from issuance of 2027 convertible notes						4,084,000
payment in connection with 2024 senior notes						0
payment of debt issuance costs
payment of royalty rights						-667,000	0			-458,000	-12,000
proceeds from issuance of common stock						0	0			0	0	0	44,861,000
other financing activities		458,000
cash and cash equivalents at end of year
net cash paid (refunded) for income taxes		607,000	1,129,000	2,266,000	29,000				-8,360,000
proceeds from sale of investments														0	0
proceeds from the issuance of common stock
proceeds from exercise of stock options										0	0
payment in settlement of convertible debt inducement					-10,500,000
payment of taxes related to net share settlement of equity awards					-722,000
payments in connection with convertible notes										0
shares withheld for payment of employee's withholding tax liability						-165,000	-28,000	-81,000	-598,000	-2,000	-9,000	-19,000	-388,000		27,000
net cash received for refund of income taxes
supplemental disclosure of non-cash investing activities
deferred payments for acquisition of otrexup intangible assets
recurring fair value measurement of assets and liabilities							3,900,000	1,300,000	1,645,000	2,011,000	300,000	2,195,000	-593,000	-356,000	1,856,000
benefit from inventory and other assets							569,000	228,000	31,000		-226,000	-11,000	151,000		753,000
payments in connection with 2021 convertible notes
net cash refunded for income taxes							538,000
amortization of royalty rights
payment in connection with series a-1 and a-2 debt										-4,750,000	0
amortization of debt discount, debt issuance costs and royalty rights									28,000	35,000	41,000	48,000	70,000	66,000
impairment of goodwill
loss on disposal of equipment and early termination of leases
income tax provision
gain on sale of gralise														0	0
loss on sale of nucynta														0	0
loss on extinguishment of convertible notes
loss on prepayment of senior notes														0	0
income taxes
cash acquired in zyla merger														0	0
proceeds from sale of nucynta														0	0
proceeds from sale of gralise														0	0
payments in connection with senior notes settlement															0
payments on promissory note														0	0
payments on revolver														0	0
net cash refund of income taxes
acquisition of otrexup intangible assets
other
payments in connection with convertible notes extinguishment															0
impairment of goodwill and intangible assets
gain on extinguishment of convertible notes														0
income taxes receivable
purchases of marketable securities
maturities of marketable securities
sales of marketable securities
payments in connection with debt extinguishment
repayment of senior notes
payment in connection with 13% senior secured notes
payment of contingent consideration liability
payment of royalty rights obligation
payment of employees' tax liability related to common shares withheld
convertible notes issuance costs
fees for modification of senior notes
net decrease in cash and cash equivalents														-13,951,000
net cash refund of (paid for) income taxes
capital expenditures incurred but not yet paid
loss on disposal of equipment
deferred income tax benefit
income tax receivable
income taxes payable
accretion of debt discount and debt issuance costs

We provide you with 20 years of cash flow statements for Assertio stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Assertio stock. Explore the full financial landscape of Assertio stock with our expertly curated income statements.

The information provided in this report about Assertio stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.